Zanubrutinib
Brukinsa · BTK inhibitor
Tumor lysis in CLL/lymphoma.
Calquence · Acala
BTK inhibitor · approved 2017 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A more selective second-generation BTK inhibitor — less hypertension than ibrutinib, with tumor lysis the main renal risk.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hypertension occurs but is less frequent than with ibrutinib (~15% vs ~26% in a matched real-world cohort; ELEVATE-RR confirmed lower hypertension and atrial fibrillation head-to-head). One single-center cardio-oncology cohort still found ~49% new/worsened hypertension by sensitive criteria. Tumor lysis is the principal route to AKI; direct nephrotoxicity is case-level.Source: Majrashi et al., Pharmacol Res Perspect 2025 (HTN 15%)
Tumor lysis early (first cycle); hypertension over weeks to months.
Distilled from: “Tumor lysis early (first cycle); hypertension over weeks–months.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
In ELEVATE-RR (head-to-head vs ibrutinib in relapsed/refractory CLL, n=533), any-grade hypertension was markedly less frequent with acalabrutinib, with a ~2.8-fold lower exposure-adjusted incidence than ibrutinib — a milder BTK-inhibitor vascular signal. PMID 37390310 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
More selective covalent BTK inhibitor (binds cysteine-481) with substantially fewer off-target kinase effects than ibrutinib, used in CLL/SLL and mantle-cell lymphoma.
Class-level context for the major non-renal toxicities of the BTK inhibitor class.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 12,744 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
2,699 of 12,744 reports
Reported with hospitalization
3,481 of 12,744 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Acalabrutinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Brukinsa · BTK inhibitor
Tumor lysis in CLL/lymphoma.
Scemblix · BCR-ABL STAMP inhibitor
Hypertension and pancreatitis; allosteric BCR-ABL inhibitor.
Adcetris · Antibody-drug conjugate (CD30/MMAE)
Tumor lysis in lymphoma.
Polivy · Antibody-drug conjugate (CD79b/MMAE)
Tumor lysis; emerging renal data.
Jaypirca · Non-covalent BTK inhibitor
2023 BTK inhibitor; tumor lysis risk.
Epkinly · Bispecific (CD20×CD3)
CRS and tumor lysis — emerging.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.